Upgrade to SI Premium - Free Trial

BofA Securities on Arcus Biosciences (RCUS): MRK Ph3 miss offers 'mixed' readthrough

April 21, 2026 10:56 AM
BofA Securities analyst Jason Zemansky reiterated a Neutral rating and $25.00 price target on Arcus Biosciences (NYSE: RCUS)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments